Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Clinical and Experimental Metastasis is Scopus-indexed (Q1, CiteScore 7.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media B.V..
Checked against the index lists dated .
ISSN 0262-0898Verify ISSN ↗1573-7276Verify ISSN ↗
Publisher: Springer Science and Business Media B.V.
Cost to publish: About US$5,090 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 79 / 428 | 81st | Q1 |
| Cancer Research | 70 / 233 | 70th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1983–present, best quartile Q1, CiteScore 7.4.
Clinical and Experimental Metastasis is Q1 in Oncology (rank 79 of 428) and Q2 in Cancer Research (rank 70 of 233), by CiteScore 2025.
Clinical and Experimental Metastasis is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 7.4, which places it in quartile Q1 at the 81st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.187, quartile Q1, with an H-index of 114.
The publisher lists an article processing charge of about US$5,090 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Clinical and Experimental Metastasis is published by Springer Science and Business Media B.V. Its print ISSN is 0262-0898 and its online ISSN is 1573-7276.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Clinical and Experimental Metastasis has an h-index of 127 and a 2-year mean of 4.13 citations per paper (OpenAlex). Its Scopus CiteScore is 7.4, quartile Q1. On 2-year citations it ranks #78 of 424 Scopus journals in Oncology.
Clinical and Experimental Metastasis published 59 papers in 2025; its busiest recent year was 2024 with 75. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2024–2026), authors are most often from China (29.8%), United States (14.7%) and Italy (7.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (0.4 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.